Navigation Links
Sofie Biosciences Launches a High Performance, Benchtop Preclinical PET System Using New Generation Detector Technology
Date:4/4/2011

CULVER CITY, Calif., April 4, 2011 /PRNewswire/ -- Sofie Biosciences, a developer of molecular imaging systems and agents, announced the launch of GENISYS4, their new benchtop small animal PET system. Introduced today at the 2011 American Association for Cancer Research Annual Meeting, this compact, preclinical multimodality PET system provides researchers with the ability to non-invasively visualize and measure the biology of disease and therapeutic response over the course of a study.

(Logo: http://photos.prnewswire.com/prnh/20101208/LA13841LOGO)

As molecular imaging becomes an essential tool for translational research, Sofie believes it is time for PET technology to be more widely accessible, cost-effective, and convenient for integration into a variety of labs.

To achieve this, PET must reduce its size and complexity while increasing usability and performance.  Furthermore, the valuable animal models at the heart of the study should have their physiology carefully maintained over the course of the experiment. GENISYS4 is the answer, utilizing new advances in detector architecture to offer unmatched sensitivity, and novel Docking Station and Imaging Chamber designs to provide safe conditions in an intuitive workflow experience. Compared to the traditional small animal PET systems that are three times the cost and ten times the size, GENISYS4 doesn't require specially trained personnel or expensive site planning to have researchers up and running with minimal cost and effort.

"GENISYS4 is launching an era of compact molecular imaging systems, just as PC companies have created a new world away from mainframes. At only 18 inches wide and 24 inches tall, GENISYS4 is the smallest PET imaging system in the industry, yet the most sensitive," said Patrick Phelps, Sofie Biosciences' President and Chief Executive Officer. "We are very excited to be the first to introduce a benchtop PET system as we join the efforts of other companies developing compact, simple, high-performance molecular imaging systems."

For additional information on Sofie's portfolio of technologies, please visit http://www.sofiebio.com.

About Sofie Biosciences 

Sofie is combining new PET imaging agents with innovative imaging systems to provide researchers and physicians with tools to better investigate the biology of disease. By empowering a wide array of people with valuable, translational imaging tools, Sofie is making PET scans more accessible and increasing the diversity of its applications.

For additional information contact Dr. Jennifer Cho at 424.223.6948 or jennifer.cho@sofiebio.com.


'/>"/>
SOURCE Sofie Biosciences
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Sofie Biosciences Raises $2M to Support Development of Diagnostic Imaging Agents and Devices
2. Regado Biosciences, Inc. Presents Results of the RADAR Phase 2b Clinical Trial of its REG1 Anticoagulation System
3. Neurocrine Biosciences to Present at the 10th Annual Needham Healthcare Conference
4. Regado Biosciences to Present at the Needham & Companys 10th Annual Healthcare Conference in New York City
5. Regado Biosciences, Inc. Announces Presentation of the Results of the RADAR Phase 2b Clinical Trial of Its Anticoagulant System REG1 at the i2 Summit During the American College of Cardiology 2011 60th Annual Scientific Session & Expo in New Orleans
6. Neurocrine Biosciences to Present at the Roth 23rd Annual OC Growth Stock Conference
7. Sangamo BioSciences Announces Presentation at the Cowen and Company 31st Annual Health Care Conference
8. Sangamo BioSciences Announces Presentation of Positive Clinical Data From Novel ZFN Therapeutic Approach for the Treatment of HIV/AIDs at Conference for Retroviral and Opportunistic Infections
9. Neurocrine Biosciences to Present at Citis 2011 Global Health Care Conference
10. Regado Biosciences to Present at the 2011 RBC Capital Markets Healthcare Conference in New York City
11. Avantra Biosciences and MedTrust Online Partner to Develop Clinically Important Protein Biomarker Assays for Improving Cancer Care
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/12/2017)... , Oct. 12, 2017 AVACEN Medical ... the company with their  2017 New Product Innovation Award ... on extensive primary and secondary medical device market research by ... through its first-to-market OTC, drug-free pain relief product, the AVACEN ... approach to treating fibromyalgia widespread pain. ...
(Date:10/11/2017)... Oct. 11, 2017  True Health, a leader ... its effort during National Breast Cancer Awareness month ... risks. Research ... calculated that more than 10 million American women ... in BRCA1 or BRCA2 and have not had testing. ...
(Date:10/5/2017)... Oct. 5, 2017  In response to the ... and Maxillofacial Surgeons (AAOMS) released prescribing recommendations that ... be used as a first-line therapy to manage ... Recognizing the value and ... Paper "Opioid Prescribing: Acute and Postoperative Pain Management" ...
Breaking Medicine Technology:
(Date:10/13/2017)... ... October 13, 2017 , ... The International Association of Eating ... excellence for the field of eating disorders, announces the opening of early registration ... Orlando, Florida at the Omni Resort at ChampionsGate. , The annual ...
(Date:10/13/2017)... LUIS OBISPO, Calif. (PRWEB) , ... October 13, 2017 , ... ... Alzheimer’s or dementia. However, many long-term care insurance companies have a waiver for care ... is the 90-day elimination period, when the family pays for care, is often waived, ...
(Date:10/13/2017)... (PRWEB) , ... October 13, 2017 , ... ... will be giving viewers the lowdown on sciatica in a new episode of ... that focuses on current events and innovation and investigates each subject in-depth with ...
(Date:10/12/2017)... ... 12, 2017 , ... CitiDent and San Francisco dentists, Dr. ... Oventus O2Vent technology. As many as 18 million Americans are estimated to suffer ... Oral appliances can offer significant relief to about 75 percent of people with ...
(Date:10/12/2017)... (PRWEB) , ... October 12, 2017 , ... ... AccentCare, a leader in post-acute health care, have expanded their existing home health ... Home Health. , AccentCare has been operating a joint venture home health company ...
Breaking Medicine News(10 mins):